For further advance psoriasis slow disease management, the standard diagnosis and treatment of patients with psoriasis by psoriasis skin venereology branch of Chinese medical association professional committee and health services in anhui province association of speaking, "2020 China psoriasis refers to southern China dandelion action and GPA online training session for the 27th session on December 26, 2020 in optimal successfully convened a doctor online platform.

        The meeting by fudan university, huashan hospital dermatology institute director, distinguished professor of dermatology, the sino-japanese friendship hospital, anhui medical university complicated severe skin disease collaborative innovation center, the international association of psoriasis, director of the committee members, psoriasis, director of the professional committee of Chinese medical association members and chief expert professor zhang and the first affiliated hospital of wenzhou medical university dermatologist dermatology, zhejiang medical association, director of the branch, deputy director of the committee co-chaired the professor zhi-ming li. Peking University third hospital director, director of the physician, the Chinese medical association of skin venereology branch of the psoriasis group deputy team leader, professor zhang cl run run shaw hospital affiliated to zhejiang university dermatologist professor zhu can be built, fudan university, huashan hospital Dr Patrick chang international medical center, cangnan Ding Zhengan professor, director of the people's hospital dermatology, wenzhou Lin Xiaomin professor, director of the center hospital dermatological department, national dermatologist fellow such as more than four hundred people attended the online meeting.

        The conference was co-chaired by Professor Zhang Xuejun and Professor Li Zhiming. First, Professor Zhang Chunlei explained the Chinese psoriasis diagnosis and treatment guide - Western medicine in detail from the concept, epidemiological characteristics, etiology and pathogenesis, diagnosis and differential diagnosis, clinical classification, severity classification and treatment of psoriasis. Based on his own clinical experience, Professor Zhang made a comprehensive analysis of the diversity and individuality of treatment, and also emphasized the significance of local treatment, phototherapy, traditional therapeutic drugs and biological agents for clinical treatment.

        Professor Zhu Kejian gave a detailed interpretation of Expert Consensus on Biotherapy for Psoriasis in China (2019). Mainly includes the formation of consensus and statement, set the basis of this agreement, this agreement covering a range of biological agents, all kinds of biological agents of clinical application, the application of biological treatment of principles and recommendations, biological treatment before the screening and treatment of monitoring, biological agents, and other treatment methods in the process of joint application, the curative effect of biological treatment of attenuation phenomenon and countermeasures and the application of the biological preparation special people. It was revealed that biological agents, as a new method, are being used more and more widely in clinical practice, which can rapidly and safely control psoriasis and improve the quality of life of patients. Meanwhile, attention should also be paid to the risk of infection brought by biological agents, and systematic screening of patients should be carried out before treatment.

        Dr Patrick chang to the key points in the clinical application of biological agents psoriasis, mainly covers the timing and matters needing attention of the intervention of biological agents, biological agents, long-term use of the efficacy and safety of withdrawal, biological preparations or treatment after treatment outcome, merge chronic infection of psoriasis psoriasis how to choose the biological agents and special people how to choose the biological agents. The factors to be considered before the use of biological agents, such as contraindications, vaccines, surveillance, comorbidities, patients at high risk of opportunistic infections, etc., were also introduced. The suggestions on the use of biological agents for psoriasis based on age and the use of biological agents for psoriasis based on pregnancy status were also introduced. So that the attending doctors have a better understanding of the key points of attention in the treatment of biological agents for psoriasis.

        At the beginning of the second half of the meeting, Professor Ding Zhengan explained China GPA project introduction, task arrangement and questionnaire filling training. Professor ding first psoriasis for China introduces the monitoring project (CGPA) project, GPA is a long-term project, is for the purpose of continuous improvement on psoriasis cognition, and reveal its affect how individuals and the society as a whole, the first phase focused on in the prevalence of psoriasis and epidemic situation, future plans to add including diagnosis and treatment of psoriasis, complications work and improve patients' quality of life, the economic burden, etc. The objective of CGPA is to understand the distribution, disease status, disease burden, economic burden and quality of life of psoriasis patients in China. The establishment of a psoriasis research cohort, long-term follow-up of patients, to improve the status of health care for psoriasis, reduce the burden on patients, improve the quality of life of patients, so as to provide information for China's research on the disease, policy and health care. At the present stage, GPA psoriasis patients are recruited to participate in psoriasis questionnaire nationwide based on GPA China monitoring site and psoriasis specialty clinic, and the epidemiological survey of GPA psoriasis patients is completed. Then Professor Ding introduced CGPA electronic system training in detail.

    Professor Lin Xiaomin, with the title "How to Use biologics for Patients with Psoriasis in Special Population", explained that biologics have excellent curative effect and good safety, making psoriasis treatment step into a new era. Biologic agents are used in different types of special population with different treatment regimens, which should be analyzed on a case-by-case basis to avoid the occurrence of adverse events. The main contents include how to use biological agents in special groups, including minors, pregnant and lactating mothers, the elderly and patients with chronic infections.

        At last, Professor Li Zhiming made a summary of this meeting, I believe that through this meeting can make the treatment of psoriasis more standardized, so that more patients with psoriasis can get personalized, optimal treatment. With the joint efforts of the psoriasis professional Committee, psoriasis outpatient department, psoriasis Research Center and GPA member unit in China, Chinese data can be provided for the global epidemiological resources of psoriasis, so that the results can better guide clinical work.

Writing: He Lili, dermatologist, The First Affiliated Hospital of Wenzhou Medical University